Form 7 Monthly Progress Report June 2025
Form 7 Monthly Progress Report May 2025 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 105,090,213 July 3, 2025 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
Press Release – BioMark Diagnostics Announces Breakthrough Publication Reinforcing Leadership in AI-Powered Metabolomics for Oncology
Novel Graph Neural Network (N-GNN) Model Achieves Superior Accuracy in Early Lung Cancer Detection, Paving the Way for Enhanced Diagnostic Capabilities. Vancouver, British Columbia – (May 20, 2025) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a leader in developing liquid biopsy tests for early cancer detection, today announced the publication of […]
Form 7 Monthly Progress Report May 2025
Form 7 Monthly Progress Report May 2025 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 105,090,213 June 1, 2025 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
BioMark Diagnostics Announces Landmark Publication Validating High Specificity and Accuracy of its Early-Stage Lung Cancer Test
Study Published in a special issue of International Journal of Molecular Sciences Confirms Test’s Ability to Distinguish Early Lung Cancer from Other Non-Cancerous Lung Diseases Vancouver, British Columbia – (May 12, 2025) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a leading developer of liquid biopsy tests for early cancer detection, today […]
BioMark Diagnostics Announces Uplisting to OTCQB Venture Market
Milestone strengthens transparency and credibility as the Company advances commercialization of its metabolomics technology platform Vancouver, British Columbia – (May 8th, 2025) BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (OTCQB: BMKDF) (FSE: 20B), a leading developer of liquid biopsy tests for early cancer detection, is pleased to announce that its common shares have […]
Form 7 Monthly Progress Report April 2025
Form 7 Monthly Progress Report May 2025 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 105,090,213 May 1, 2025 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
Form 7 Monthly Progress Report March 2025
Form 7 Monthly Progress Report February 2025 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 105,090,213 April 5, 2025 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
BioMark Announces the Final Closing of Oversubscribed Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. BioMark Announces the Final Closing of Oversubscribed Private Placement Vancouver, British Columbia – (March 31, 2025) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a leading developer of liquid biopsy tests for early cancer detection, today announced the […]
BioMark Secures Financing for Initial Tranche to Advance Early-Detection Oncology Testing Platform
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. BioMark Secures Financing for Initial Tranche to Advance Early-Detection Oncology Testing Platform Vancouver, British Columbia – (March 26, 2025) BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a leading developer of liquid biopsy tests for early cancer detection, is […]
Remembering Mia Love: A Trailblazer’s Legacy and Biomark’s Fight Against Cancer
Personal Reflection: A Shared Journey of Loss and Hope My journey with BioMark Diagnostics is deeply personal. Two years ago, I lost my sister in the UK to glioblastoma (GBM), a journey that began with breast cancer that tragically metastasized to her brain. I flew to London, spending the last six weeks by her side, […]
